araag2/HINT huggingface dataset:
Clinical trial NCT00684099 (phase 1/phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, pemetrexed
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed inoperable (stage IIIB-IV) NSCLC. A block of Formaline Fixed
             Parafine Embedded tissue representative for the primary diagnosis should be available
             for genomic analysis (phase II part)

          -  Written informed consent

          -  Prior chemotherapy with platinum compounds in association with or without taxanes
             (phase I part)

          -  Previously untreated with docetaxel and pemetrexed (phase II part)

          -  Bidimensionally, non-irradiated measurable disease (according to RECIST criteria)
             (phase II)

          -  Age ≥18 years

          -  World Health Organization (WHO) performance status (PS) 0-2

          -  Life expectancy of at least 12 weeks

          -  Serum bilirubin less than 1.5 times the upper normal limit (UNL)

          -  AST and ALT less than 2.5 times the UNL in the absence of demonstrable liver
             metastases, or less than 5 times the UNL in the presence of liver metastases.

          -  Serum creatinine less than 1.5 times the UNL

          -  Neutrophil count more than 1.5x 109 /L

          -  Platelet count more than 100x 109 /L

        Exclusion Criteria:

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years (with
             the exception of basal cell carcinoma or cervical cancer in situ)

          -  Any evidence of severe uncontrolled concomitant disease (in the opinion of the
             investigator)

          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  Patients with unstable central nervous system metastases

          -  Malnutrition (loss of ≥ 20% of the original body weight)

          -  Performance status: 4

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
Clinical trial NCT01463488 (phase 1, status: completed)
Conditions: knee osteoarthritis
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: sar113945, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        - Diagnosis of primary knee osteoarthritis, based upon the following:

          -  X-ray or Magnetic Resonance Imaging (MRI) evidence within the last 6 months for joint
             space narrowing and osteophyte formation

          -  Patients will be Kellgren and Lawrence classification II/III, and total Western
             Ontario McMaster (WOMAC) score 24 -72.

          -  Patients fulfilling the American College of Rheumatology Clinical and Radiographic
             criteria for Osteoarthritis.

        Exclusion criteria:

          -  Patients younger than 40 years

          -  Women of child bearing potential.

          -  Women either sterilized for more than 3 months, or post-menopausal for more than 12
             months. Menopause is defined as over age of 60 years or being amenorrheic for at least
             2 years with plasma FSH level >30 IU/L.

          -  Secondary osteoarthritis: e.g., autoimmune disease, joint dysplasia, aseptic
             osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease,
             Stickler's syndrome, joint infection, haemophilia, haemochromatosis, calcium
             pyrophosphate deposition disease, or neuropathic arthropathy.

          -  Presence of local skin abnormality at the affected knee joint.

          -  Intra-articular injection within 3 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00583102 (phase 1/phase 2, status: terminated)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cytarabine, lovastatin
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)C1=CN=CC=C1
Reason stopped: 
    slow accrual, pi left institution
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with primary refractory AML (that is no prior remission). Patients who have
             greater than 10% AML blasts in the bone marrow or blood upon recovery from two cycles
             of standard cytarabine- and anthracycline-based induction chemotherapy are eligible.
             Patients who have received etoposide and/or 6-thioguanine during remission induction
             will be eligible.

          -  Patients with relapsed AML. Patients must have had a documented remission lasting > 30
             days at some point during their prior therapy. Their current relapse must be
             untreated. Relapse is defined as the presence of greater than 10% AML blasts in the
             bone marrow or blood after having had a documented remission.

          -  Patients who have received a high-dose cytarabine containing regimen (>2 g/m2/dose)
             within 3 months prior to registration on this protocol are not eligible.

          -  No active CNS involvement. A lumbar puncture prior to treatment is not required and
             should not be performed in the absence of significant CNS symptoms or signs.

          -  Non-pregnant and non-nursing. Treatment under this protocol would expose an unborn
             child to significant risks. Women and men of reproductive potential should agree to
             use an effective means of birth control.

        Exclusion Criteria:

        Although NOT considered formal Exclusion Criteria, study physicians are strongly encouraged
        as part of this decision-making process to recognize that the following may increase the
        risks to a subject entering this protocol:

          -  Other serious illnesses which would limit survival to <2 years, or a psychiatric
             condition which would prevent compliance with treatment or informed consent.

          -  Performance Status > 2.

          -  Uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or
             infection, which in the opinion of the treating physician, would make this protocol
             treatment unreasonably hazardous for the patient.

          -  Patients with a "currently active" second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a "currently active" malignancy if they
             have completed therapy and considered by their physician to be at less than 30% risk
             of relapse within one year.

          -  Patients who have received any investigational agent within the prior 4 weeks.
Clinical trial NCT00590603 (phase 1, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: arsenic trioxide, ascorbic acid and bortezomib
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Reason stopped: 
    poor accrual - terminated during phase i; phase ii never started.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of relapsed/refractory multiple myeloma.

          -  Patients must have measurable disease, defined as localized plasmacytoma, detectable
             M-spike by serum protein electrophoresis (SPEP) and/or urine protein electrophoresis
             (UPEP), or free light chain assay, bone lytic lesions and/or bone marrow infiltration
             with atypical plasma-cells.

          -  Patients must be at least four weeks since their prior therapy. Patients will not be
             excluded because of any prior regimen they have received as long as they meet other
             requirements.

          -  Adequate organ function, patients with elevated creatinine due to myeloma are not
             excluded

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Serum potassium greater than 4.0 milliequivalent (mEq)/dL and serum magnesium greater
             than 1.8 mg/dL. If these electrolytes are below the specified limits on the baseline
             laboratory tests, supplemental electrolytes should be administered to bring the serum
             concentrations to these levels before administering arsenic trioxide.

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Bortezomib, Trisenox, Ascorbic acid, or other agents used in the study.

          -  Corrected QT interval (QTc) interval greater than 460 msec in the presence of serum
             potassium greater than or equal to 4.0 mEq/L and magnesium greater than or equal to
             1.8 mg/dL, or underlying conduction disease that prevents measurement of the QTc
             interval.

          -  History of ventricular tachycardia or any cardiac arrhythmia requiring the placement
             of an automated intraventricular cardiac defibrillator or therapy with class I or
             class II antiarrhythmic drug.

          -  Ejection fraction (EF) by multigated acquisition (MUGA) scan less than 35%.
Clinical trial NCT00099086 (phase 1, status: active, not recruiting)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: bicalutamide, docetaxel, gnrh analog
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)O
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the prostate with one of the prognostic
             factors specified in the protocol. No pelvic lymph node disease that would necessitate
             pelvic radiotherapy. No radiologic evidence of metastatic disease on bone scan or on
             CT scan or MRI of the abdomen or pelvis

          2. No prior radiation therapy, chemotherapy, immunotherapy or alternative therapy for
             prostate cancer. Greater than 4 weeks since any major surgery.

          3. Performance status 0-2

          4. Must meet criteria for acceptable lab values as outlined in the protocol.

          5. Peripheral neuropathy must be greater than or equal to 1

          6. Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

        Exclusion Criteria:

        1. No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
        with Polysorbate 80
Clinical trial NCT01381107 (phase 1/phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: alks 5461, placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects between 18 and 65 years of age, inclusive.

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
             (DSM-IV-TR) criteria for MDD.

          -  Current episode lasting ≥8 weeks prior to screening with an inadequate/partial
             response to an adequate trial (defined as at least 8 weeks) of a stable dose of an
             SSRI or SNRI. Inadequate/partial response is defined as:

               1. A Hamilton Depression Rating Scale total score (HAM-D17) ≥14, and

               2. Less than 50% reduction in depressive symptom severity on the Massachusetts
                  General Hospital Antidepressant Treatment Response Questionnaire (ATRQ), and

               3. Clinical Global Impression - Severity (CGI-S) score of ≥3.

        Exclusion Criteria:

          -  Axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder,
             schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder,
             obsessive-compulsive disorder, panic disorder, or posttraumatic stress disorder.

          -  A clinically significant current Axis II diagnosis of borderline, antisocial,
             paranoid, schizoid, schizotypal, or histrionic personality disorder.

          -  Experiencing hallucinations, delusions, or any psychotic symptomatology in the current
             episode.

          -  The use of inducers or inhibitors of cytochrome P450 (CYP) 3A4 (prescription
             medications, over-the-counter [OTC] medications, or dietary supplements) within 30
             days before dosing.

          -  Have received electroconvulsive therapy during the current MDD episode.

          -  Pose current suicide risk as confirmed by the Columbia Suicide Severity Rating Scale
             (C SSRS).

          -  History of intolerance or hypersensitivity to buprenorphine.

          -  History of allergy or hypersensitivity to opioid antagonists (eg, naltrexone,
             naloxone) or quinine.
Clinical trial NCT01359579 (phase 1, status: terminated)
Conditions: renal impairment
ICD codes: M10.38, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322
Drugs: varespladib methyl
SMILES: CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females 18 years or older with a BMI of 18-40
             kg/m2 inclusive.

          -  Regarding renal function, subjects will be classified as either normal or as suffering
             from mild,moderate or severe renal impairment. Classification of renal impairment will
             be estimated by the MDRD and Cockcroft-Gault formulae

        Exclusion Criteria:

          -  Any disease, condition and/or chronic medications which might compromise the
             hematologic, cardiovascular, pulmonary renal, gastrointestinal, hepatic, or central
             nervous system; or other conditions that might interfere with the distribution,
             metabolism or excretion of study drug, or would place the subject at increased risk

          -  Evidence of significant respiratory, gastrointestinal or hepatic disease at screening

          -  Positive screen for hepatitis B surface antigen, or HIV

          -  Positive test in drugs of abuse screens or alcohol on admission to the clinic
Clinical trial NCT01565746 (phase 1, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: radium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223)
SMILES: Cl[223Ra]Cl, Cl[223Ra]Cl, Cl[223Ra]Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male ≥ 20 years of age

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within
             the previous 4 weeks

          -  Patients who has failed initial hormonal therapy using either an orchiectomy or a
             Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must
             first progress through antiandrogen withdrawal prior to being eligible. The minimum
             timeframe to document failure of anti-androgen withdrawal will be four weeks

          -  Progressive castration resistant metastatic disease

          -  Castrate level of testosterone (<50 ng/dL), treatment to maintain castrate levels of
             testosterone must be continued

        Exclusion Criteria:

          -  Has received an investigational drug in the 4 weeks before or is scheduled to
             receiving one during or in the 8 weeks after study drug administration.

          -  Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry
             in the study, or has not recovered from acute adverse events as a result of such
             therapy

          -  Has received prior hemibody external radiotherapy

          -  Has a need for immediate external radiotherapy

          -  Has received systemic radiotherapy with radium-223, strontium-89, samarium-153,
             rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24
             weeks prior to administration of study drug

          -  When receiving bisphosphonates, has changed the dose within 4 weeks before
             administration of study drug
Clinical trial NCT01294540 (phase 1, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: drug: e2609, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion:

          -  Healthy males and females

          -  Aged 30 to 55 years, inclusive (Cohorts 1 through 5); aged 65 to 85 years, inclusive
             (Cohort 6)

          -  Body mass index (BMI) of 18 to 32kg/m^2 at Screening

          -  Additional inclusion criteria for Cohort 6 (healthy elderly subjects)

        Exclusion

          -  Females of child-bearing potential

          -  Personal or family history of neurological abnormalities

          -  Any clinical abnormality of the electrocardiogram (ECG)at Screening and check-in

          -  A family history of cardiac abnormalities

          -  Thyroid abnormalities
Clinical trial NCT00221325 (phase 1, status: completed)
Conditions: central nervous system lymphoma, intraocular lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: intraventricular rituximab plus mtx
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Relapsed, refractory CNS lymphoma, ocular lymphoma, lymphomatous meningitis

          2. Tumors must be CD20 + on pathologic analysis.

          3. Patients must have an Ommaya reservoir (ventricular access device.

          4. Patients may have had prior intrathecal methotrexate, ara-C or thiotepa but must have
             recovered from any reversible toxicity caused by prior treatment.

          5. Concurrent systemic chemotherapy is allowed for treatment of disease outside the
             meninges with the exception of high-dose methotrexate (>500 mg/m2/d, high-dose ara-C
             (> 2 gm/m2/d), high-dose thiotepa (>300 mg/m2/d) or investigational agents.

          6. Patients must have sufficient baseline hematologic function: >1,500 granulocytes and
             >50,000 platelets/ul.

          7. Patients must have had a nuclear medicine CSF flow study performed within 30 days of
             treatment which shows no significant obstruction within the ventricles.

        Exclusion Criteria:

          1. History of whole brain or craniospinal irradiation or intrathecal chemotherapy < 4
             days before initiation of intra-CSF administration of rituximab.

          2. Anticipated survival of less than one month.

          3. HIV infection. -
Clinical trial NCT00447421 (phase 1/phase 2, status: terminated)
Conditions: small cell lung cancer, carcinoma, small cell, sclc
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    interim results of another trial showed inferior activity of treatment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable disease with diagnosis of Small Cell Lung Cancer.

          -  Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance
             status schedule.

          -  Patients must be at least 18 years of age and have at least a 12-week life expectancy.

          -  No prior chemotherapy and/or prior thoracic radiotherapy.

          -  Adequate pulmonary function and organ function.

        Exclusion Criteria:

          -  Patients with myocardial infarction within the preceding six months.

          -  Diagnosis of a serious concomitant systemic disorder.

          -  Prior radiotherapy to the lower neck or abdominal region.

          -  Significant weight loss.

          -  Concurrent administration of any other antitumor therapy.
Clinical trial NCT01514578 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: trv130a, dextrose in water
SMILES: [H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy adult male 19 - 50 years of age

          -  Body weight >/= 50 kg

          -  Capable of giving written informed consent

        Exclusion Criteria:

          -  Clinically significant disease or conditions that may place the subject at
             unacceptable risk as a participant in the study, or that may interfere with the
             safety, tolerability or pharmacodynamic evaluations in the study

          -  Laboratory tests positive for HIV, Hepatitis B virus surface antigen, or Hepatitis C
             virus antibody; elevations of aspartate aminotransferase or alanine aminotransferase;
             positive drug or alcohol test; positive urine test for cotinine

          -  Major surgery within 4 weeks of screening
Clinical trial NCT01208831 (phase 1, status: completed)
Conditions: advanced solid tumor cancers, medulloblastoma, basal cell carcinoma
ICD codes: C44.510, C44.91, C44.01, C44.311, C44.511, C44.81, C44.41
Drugs: lde225
SMILES: [H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1
Eligibility criteria:

        Inclusion Criteria:

          -  confirmed diagnosis of advanced solid tumor (including medulloblastoma and basal cell
             carcinoma)

          -  blood work criteria

        Exclusion Criteria:

          -  patients with history of brain tumor (except recurrent medulloblastoma) or brain
             metastases

          -  positive HIV, hepatitis B or C

          -  impaired intestinal function

          -  impaired heart function

          -  pregnant or breast-feeding women

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00719524 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ombrabulin (ave8062)
SMILES: COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1NC(=O)[C@@H](N)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced neoplastic disease (i.e. metastatic or locally advanced disease) for which
             platinum-taxane doublet regimens are approved or constitutes the mainstay of care such
             as non small cell lung cancer, epithelial ovary cancer, gastric cancer, transitional
             cell and bladder cancer and head and neck cancer.

          -  Eastern cooperative oncology group (ECOG) performance status of 0 to 1.

        Exclusion Criteria:

          -  Concurrent treatment with any other anticancer therapy, including chemotherapy,
             immunotherapy, radiotherapy (excluding radiotherapy with palliative intent on
             non-target lesions), targeted therapy, gene therapy, or patients planning to receive
             these treatments during the study.

          -  Absence of histologically or cytologically proven cancer at the first diagnosis.

          -  Negative serum/urinary pregnancy test

          -  Washout period of 3 weeks for prior anti-tumor therapy or any investigational
             treatment

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.